SCHEMBL7967305

SCHEMBL7967305

[CH2]OCc1cc(C)c2ccccc2n1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.53
BACE1 P56817 1/20 0.50
PDE10A Q9Y233 3/20 0.46
KDM4E B2RXH2 6/20 0.45
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HPGD P15428 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
LMNA P02545 2/20 0.44
RAB9A P51151 3/20 0.44
POLB P06746 2/20 0.44
MAPT P10636 2/20 0.44
GAA P10253 2/20 0.43
NPFFR1 Q9GZQ6 1/20 0.43
NPFFR2 Q9Y5X5 1/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7967311 0.85 CYP1A2 (0.55) CYP1A2BACE1PDE10AKDM4EALDH1A1
SCHEMBL28585633 0.82 CYSLTR1 (0.57) CYP1A2BACE1PDE10AKDM4EALDH1A1
SCHEMBL25523802 0.81 KDM4E (0.50) CYP1A2BACE1PDE10AKDM4EALDH1A1
SCHEMBL25523858 0.80 CYP1A2 (0.46) CYP1A2BACE1PDE10AKDM4EALDH1A1
SCHEMBL3969032 0.79 CYP1A2 (0.60) CYP1A2BACE1PDE10AKDM4EALDH1A1
SCHEMBL3396098 0.78 ALDH1A1 (0.49) CYP1A2BACE1KDM4EALDH1A1HPGD
SCHEMBL526457 0.77 CYP1A2 (0.58) CYP1A2BACE1PDE10AKDM4EALDH1A1
SCHEMBL4848307 0.77 CYP1A2 (0.58) CYP1A2BACE1PDE10AKDM4EALDH1A1
SCHEMBL3396050 0.77 CYP1A2 (0.58) CYP1A2BACE1PDE10AKDM4EALDH1A1
SCHEMBL28589683 0.77 CYP1A2 (0.58) CYP1A2BACE1PDE10AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6274715-B1 SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY ABBOTT LABORATORIES 2001-08-14 US claimed
EP-0961776-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES Abbott Laboratories (US) 1999-12-08 EP claimed
WO-1998030574-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1998-07-16 WO claimed
US-6274715-B1 SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY ABBOTT LABORATORIES 2001-08-14 US disclosed
EP-0961776-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES Abbott Laboratories (US) 1999-12-08 EP disclosed
WO-1998030574-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1998-07-16 WO disclosed